Document:

EX-10.2

 Exhibit 10.2 

Form of Lock-Up Agreement - Vital Therapies Officers 

Lock-Up Agreement 

April    , 2019 
 Immunic AG

 Am Klopferspitz 19 
 82152 Planegg-Martinsried 

Germany 
 Ladies and Gentlemen: 

The undersigned (the “Lock-Up Participant”) is entering into this agreement in
connection with that certain Exchange Agreement dated as of January 6, 2019 (the “Exchange Agreement”) among Vital Therapies, Inc, a Delaware corporation (“Vital”), Immunic AG (“Immunic”) and
the shareholders of Immunic, whereby the shareholders of Immunic will contribute, transfer, assign and deliver all of the Common Shares and Preferred Shares of Immunic (collectively, the “Immunic Shares”) owned by them, and all of
their rights with respect to such Immunic Shares, to Vital in exchange for shares of the common stock, par value $0.0001 per share, of Vital (the “Vital Common Stock”), with the result of Immunic becoming a wholly-owned subsidiary
of Vital (the “Transaction”) and the Lock-Up Participant, as a holder of shares of Vital Common Stock and/or shares of Vital Common Stock issuable pursuant to the exercise of Vital Options
and/or the vesting of Vital Severance RSUs. Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Exchange Agreement. 

The Lock-Up Participant hereby agrees that, without the prior written consent of Vital (or, from and
after the Effective Time, Immunic, Inc.), the Lock-Up Participant will not, during the period commencing on the date hereof and ending 180 days after the date of the Closing (the “Lock-Up Period”), (1) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or
otherwise transfer or dispose of, directly or indirectly, any shares of Vital Common Stock or any securities convertible into or exercisable or exchangeable for Vital Common Stock (including, without limitation, Vital Common Stock or such other
securities which may be deemed to be beneficially owned by the Lock-Up Participant in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or
warrant), or publicly disclose the intention to make any offer, sale, pledge or disposition; (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of Vital Common Stock or
such other securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Vital Common Stock or such other securities, in cash or otherwise or (3) make any demand for or exercise any right
with respect to the registration of any shares of Vital Common Stock or any security convertible into or exercisable or exchangeable for Vital Common Stock, in each case for purposes of clause (1) or (2) above other than (A) transfers of
shares of Vital Common Stock or such other securities as a bona fide gift or gifts, (B) distributions of shares of Vital Common Stock or such other securities to current or former, direct or indirect, members, stockholders, limited partners,
subsidiaries or affiliates (as defined in Rule 405 promulgated under the Securities Act) of the Lock-Up Participant or to any investment fund or other entity that controls or manages the Lock-Up Participant (including, for the avoidance of doubt, a fund managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by, or under common
control with such manager or managing member or general partner or management company as the Lock-Up Participant or who shares a common investment advisor with the
Lock-Up Participant) in a transaction not involving a disposition for value, (C) sales or other dispositions or arrangements involving shares of Vital Common Stock acquired in the open market after the
Closing, (D) a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Vital Common Stock involving a change of control of Vital following the Closing (including, without limitation,
entering into any lock-up, 

 
voting or similar agreement pursuant to which the Lock-Up Participant may agree to transfer, sell, tender or otherwise dispose of Vital Common Stock or
such other securities in connection with any such transaction, or vote any Vital Common Stock in favor of any such transaction), or (E) transfers of shares of Vital Common Stock owned by the Lock-Up
Participant in a private transaction; provided that in the event that the tender offer, merger, consolidation or other such transaction is not completed, the Vital Common Stock owned by the Lock-Up
Participant shall remain subject to the restrictions contained in this Lock-Up Agreement, provided, that in the case of any transfer or distribution pursuant to clause (A) or (B), each donee,
distributee or transferee shall execute and deliver to Vital a lock-up letter in the form of this Lock-Up Agreement; and provided, further, that in the
case of any transfer, distribution, sale or other arrangement pursuant to clause (A), (B), (C) or (E) no filing by any party (donor, donee, transferor or transferee) or the Lock-Up Participant, or any
director of Vital affiliated with any party (donor, donee, transferor or transferee) or the Lock-Up Participant, under the Exchange Act, or other public announcement shall be required or shall be made
voluntarily in connection with such transfer, distribution, sale or other arrangement, other than a filing on a Form 5 made after the expiration of the Lock-Up Period or any required beneficial ownership
filings under Section 13 of the Exchange Act. For purposes of this Lock-Up Agreement, “change of control” shall mean the consummation of any bona fide third party tender offer, merger,
consolidation or other similar transaction the result of which is that any “person” (as defined in
Section 13 (d) (3) of the Exchange Act) other than Vital, or group of persons other than existing stockholders of Vital, becomes the beneficial owner (as defined in
Rules 13d-3 and 13d-5 of the Exchange Act) of fifty percent (50%) of total voting power of the voting stock of Vital. 

Notwithstanding any provision herein to the contrary, the restrictions set forth herein shall not apply to any sales of Vital Common Stock by
any Lock-Up Participant solely for the purpose of settling Tax expenses in connection with the consummation of the Transaction (it being understood that 50% of the shares of Vital Common Stock issued pursuant
to vesting of the Vital Severance RSUs will be freely tradable and not subject to this Lock-Up Agreement). 

No provision in this Lock-Up Agreement shall be deemed to restrict or prohibit the exercise, exchange
or conversion by the Lock-Up Participant of any securities exercisable or exchangeable for or convertible into Vital Common Stock, as applicable; provided that the
Lock-Up Participant does not transfer the Vital Common Stock acquired on such exercise, exchange or conversion during the Lock-Up Period, unless otherwise permitted
pursuant to the terms of this Lock-Up Agreement. In addition, no provision herein shall be deemed to restrict or prohibit the entry into a 10b5-1 trading plan at any
time (other than the entry into such a plan in such a manner as to cause the sale of any securities subject to this Lock-Up Agreement during the Lock-Up Period). 

The Lock-Up Participant understands that this Lock-Up
Agreement is irrevocable and shall be binding upon the Lock-Up Participant’s heirs, legal representatives, successors and assigns. 

The Lock-Up Participant understands that if the Exchange Agreement (other than the provisions thereof
which survive termination) shall terminate or be terminated prior to Closing, then this Lock-Up Agreement shall be void and of no further force or effect. 

(Signature Page Follows) 

  
 2 

 
	
	Very truly yours,
	
	                
	(Name - Please Print)
	
	                
	(Signature)
	
	                
	(Name of Signatory, in the case of entities - Please Print)
	
	                
	(Title of Signatory, in the case of entities - Please Print)

  

			
	Address:	 	 
		
		 	        
		
		 	        

  
 3 

(Signature Page to Vital Lock-Up Agreement) 

 Form of Lock-Up Agreement - Vital Therapies Directors 

Lock-Up Agreement 

April    , 2019 
 Immunic AG

 Am Klopferspitz 19 
 82152 Planegg-Martinsried 

Germany 
 Ladies and Gentlemen: 

The undersigned (the “Lock-Up Participant”) is entering into this agreement in
connection with that certain Exchange Agreement dated as of January 6, 2019 (the “Exchange Agreement”) among Vital Therapies, Inc, a Delaware corporation (“Vital”), Immunic AG (“Immunic”) and
the shareholders of Immunic, whereby the shareholders of Immunic will contribute, transfer, assign and deliver all of the Common Shares and Preferred Shares of Immunic (collectively, the “Immunic Shares”) owned by them, and all of
their rights with respect to such Immunic Shares, to Vital in exchange for shares of the common stock, par value $0.0001 per share, of Vital (the “Vital Common Stock”), with the result of Immunic becoming a wholly-owned subsidiary
of Vital (the “Transaction”) and the Lock-Up Participant, as a holder of shares of Vital Common Stock and/or shares of Vital Common Stock issuable pursuant to the exercise of Vital Options
and/or the vesting of Vital Severance RSUs. Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Exchange Agreement. 

The Lock-Up Participant hereby agrees that, without the prior written consent of Vital (or, from and
after the Effective Time, Immunic, Inc.), the Lock-Up Participant will not, during the period commencing on the date hereof and ending 180 days after the date of the Closing (the “Lock-Up Period”), (1) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or
otherwise transfer or dispose of, directly or indirectly, any shares of Vital Common Stock or any securities convertible into or exercisable or exchangeable for Vital Common Stock (including, without limitation, Vital Common Stock or such other
securities which may be deemed to be beneficially owned by the Lock-Up Participant in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or
warrant), or publicly disclose the intention to make any offer, sale, pledge or disposition; (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of Vital Common Stock or
such other securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Vital Common Stock or such other securities, in cash or otherwise or (3) make any demand for or exercise any right
with respect to the registration of any shares of Vital Common Stock or any security convertible into or exercisable or exchangeable for Vital Common Stock, in each case for purposes of clause (1) or (2) above other than (A) transfers of
shares of Vital Common Stock or such other securities as a bona fide gift or gifts, (B) distributions of shares of Vital Common Stock or such other securities to current or former, direct or indirect, members, stockholders, limited partners,
subsidiaries or affiliates (as defined in Rule 405 promulgated under the Securities Act) of the Lock-Up Participant or to any investment fund or other entity that controls or manages the Lock-Up Participant (including, for the avoidance of doubt, a fund managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by, or under common
control with such manager or managing member or general partner or management company as the Lock-Up Participant or who shares a common investment advisor with the
Lock-Up Participant) in a transaction not involving a disposition for value, (C) sales or other dispositions or arrangements involving shares of Vital Common Stock acquired in the open market after the
Closing, (D) a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Vital Common Stock involving a change of control of Vital following the Closing (including, without limitation,
entering into any lock-up, 

 
voting or similar agreement pursuant to which the Lock-Up Participant may agree to transfer, sell, tender or otherwise dispose of Vital Common Stock or
such other securities in connection with any such transaction, or vote any Vital Common Stock in favor of any such transaction), or (E) transfers of shares of Vital Common Stock owned by the Lock-Up
Participant in a private transaction; provided that in the event that the tender offer, merger, consolidation or other such transaction is not completed, the Vital Common Stock owned by the Lock-Up
Participant shall remain subject to the restrictions contained in this Lock-Up Agreement, provided, that in the case of any transfer or distribution pursuant to clause (A) or (B), each donee,
distributee or transferee shall execute and deliver to Vital a lock-up letter in the form of this Lock-Up Agreement; and provided, further, that in the
case of any transfer, distribution, sale or other arrangement pursuant to clause (A), (B), (C) or (E) no filing by any party (donor, donee, transferor or transferee) or the Lock-Up Participant, or any
director of Vital affiliated with any party (donor, donee, transferor or transferee) or the Lock-Up Participant, under the Exchange Act, or other public announcement shall be required or shall be made
voluntarily in connection with such transfer, distribution, sale or other arrangement, other than a filing on a Form 5 made after the expiration of the Lock-Up Period or any required beneficial ownership
filings under Section 13 of the Exchange Act. For purposes of this Lock-Up Agreement, “change of control” shall mean the consummation of any bona fide third party tender offer, merger,
consolidation or other similar transaction the result of which is that any “person” (as defined in
Section 13 (d) (3) of the Exchange Act) other than Vital, or group of persons other than existing stockholders of Vital, becomes the beneficial owner (as defined in
Rules 13d-3 and 13d-5 of the Exchange Act) of fifty percent (50%) of total voting power of the voting stock of Vital. Notwithstanding any provision herein to the
contrary, the restrictions set forth herein shall not apply to any sales of Vital Common Stock by any Lock-Up Participant solely for the purpose of settling Tax expenses in connection with the consummation of
the Transaction. 
 No provision in this Lock-Up Agreement shall be deemed to restrict or
prohibit the exercise, exchange or conversion by the Lock-Up Participant of any securities exercisable or exchangeable for or convertible into Vital Common Stock, as applicable; provided that the Lock-Up Participant does not transfer the Vital Common Stock acquired on such exercise, exchange or conversion during the Lock-Up Period, unless otherwise permitted pursuant
to the terms of this Lock-Up Agreement. In addition, no provision herein shall be deemed to restrict or prohibit the entry into a 10b5-1 trading plan at any time (other
than the entry into such a plan in such a manner as to cause the sale of any securities subject to this Lock-Up Agreement during the Lock-Up Period). 

The Lock-Up Participant understands that this Lock-Up
Agreement is irrevocable and shall be binding upon the Lock-Up Participant’s heirs, legal representatives, successors and assigns. 

The Lock-Up Participant understands that if the Exchange Agreement (other than the provisions thereof
which survive termination) shall terminate or be terminated prior to Closing, then this Lock-Up Agreement shall be void and of no further force or effect. 

(Signature Page Follows) 

  
 5 

 
	
	Very truly yours,
	
	                
	(Name - Please Print)
	
	                
	(Signature)
	
	                
	(Name of Signatory, in the case of entities - Please Print)
	
	                
	(Title of Signatory, in the case of entities - Please Print)

  

			
	Address:	 	 
		
		 	        
		
		 	        

  
 6 

(Signature Page to Vital Lock-Up Agreement) 

 Form of Lock-Up Agreement - Vital Therapies Directors 

Lock-Up Agreement 

April    , 2019 
 Vital
Therapies, Inc. 
 15222-B Avenue of Science 

San Diego, California 92128 
 Ladies and Gentlemen: 

The undersigned (the “Lock-Up Participant”) is entering into this agreement in
connection with that certain Exchange Agreement dated as of January 6, 2019 (the “Exchange Agreement”) among Vital Therapies, Inc., a Delaware corporation (“Vital”), Immunic AG (“Immunic”) and
the shareholders of Immunic whereby the shareholders of Immunic will contribute, transfer, assign and deliver all of the Common Shares and Preferred Shares of Immunic (collectively, the “Immunic Shares”) owned by them, and all of
their rights with respect to such Immunic Shares, to Vital in exchange for shares of the common stock, par value $0.0001 per share, of Vital (the “Vital Common Stock”), with the result of Immunic becoming a wholly-owned subsidiary
of Vital (the “Transaction”) and the Lock-Up Participant, as a holder of Immunic Shares, will receive shares of Vital Common Stock in exchange for his, her or its Immunic Shares in connection
with the Transaction. Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Exchange Agreement. 

The Lock-Up Participant hereby agrees that, without the prior written consent of Immunic (or, from and
after the Effective Time, Vital), the Lock-Up Participant will not, during the period commencing on the date hereof and ending 180 days after the date of the Closing (the “Lock-Up Period”), (1) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or
otherwise transfer or dispose of, directly or indirectly, any shares of Vital Common Stock or any securities convertible into or exercisable or exchangeable for Vital Common Stock (including, without limitation, Vital Common Stock or such other
securities which may be deemed to be beneficially owned by the Lock-Up Participant in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or
warrant), or publicly disclose the intention to make any offer, sale, pledge or disposition; (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of Vital Common Stock or
such other securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Vital Common Stock or such other securities, in cash or otherwise or (3) make any demand for or exercise any right
with respect to the registration of any shares of Vital Common Stock or any security convertible into or exercisable or exchangeable for Vital Common Stock, in each case for purposes of clause (1) or (2) above other than (A) transfers of
shares of Vital Common Stock or such other securities as a bona fide gift or gifts, (B) distributions of shares of Vital Common Stock or such other securities to current or former, direct or indirect, members, stockholders, limited partners,
subsidiaries or affiliates (as defined in Rule 405 promulgated under the Securities Act) of the Lock-Up Participant or to any investment fund or other entity that controls or manages the Lock-Up Participant (including, for the avoidance of doubt, a fund managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by, or under common
control with such manager or managing member or general partner or management company as the Lock-Up Participant or who shares a common investment advisor with the
Lock-Up Participant) in a transaction not involving a disposition for value, (C) sales or other dispositions or arrangements involving shares of Vital Common Stock acquired in the open market after the
Closing, (D) a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Vital Common Stock involving a change of control of Vital following the Closing (including, without limitation,
entering into any lock-up, voting or similar agreement pursuant to which the Lock-Up Participant may agree to transfer, sell, tender or

 
otherwise dispose of Vital Common Stock or such other securities in connection with any such transaction, or vote any Vital Common Stock in favor of any such transaction), or (E) transfers
of shares of Vital Common Stock owned by the Lock-Up Participant in a private transaction; provided that in the event that the tender offer, merger, consolidation or other such transaction is not
completed, the Vital Common Stock owned by the Lock-Up Participant shall remain subject to the restrictions contained in this Lock-Up Agreement, provided, that in
the case of any transfer or distribution pursuant to clause (A) or (B), each donee, distributee or transferee shall execute and deliver to Vital a lock-up letter in the form of this Lock-Up Agreement; and provided, further, that in the case of any transfer, distribution, sale or other arrangement pursuant to clause (A), (B), (C) or (E) no filing by any party (donor, donee,
transferor or transferee) or the Lock-Up Participant, or any director of Vital affiliated with any party (donor, donee, transferor or transferee) or the Lock-Up
Participant, under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with such transfer, distribution, sale or other arrangement, other than a filing on a Form 5 made after the expiration of
the Lock-Up Period or any required beneficial ownership filings under Section 13 of the Exchange Act. For purposes of this Lock-Up Agreement, “change of
control” shall mean the consummation of any bona fide third party tender offer, merger, consolidation or other similar transaction the result of which is that any “person” (as defined in Section 13 (d) (3) of the Exchange Act) other than Vital, or group of persons other than existing stockholders of Vital, becomes the beneficial owner (as defined in
Rules 13d-3 and 13d-5 of the Exchange Act) of fifty percent (50%) of total voting power of the voting stock of Vital. Notwithstanding any provision herein to the
contrary, the restrictions set forth herein shall not apply to any sales of Vital Common Stock by any Lock-Up Participant solely for the purpose of settling Tax expenses in connection with the consummation of
the Transaction. 
 No provision in this Lock-Up Agreement shall be deemed to restrict or
prohibit the exercise, exchange or conversion by the Lock-Up Participant of any securities exercisable or exchangeable for or convertible into Vital Common Stock, as applicable; provided that the Lock-Up Participant does not transfer the Vital Common Stock acquired on such exercise, exchange or conversion during the Lock-Up Period, unless otherwise permitted pursuant
to the terms of this Lock-Up Agreement. In addition, no provision herein shall be deemed to restrict or prohibit the entry into a 10b5-1 trading plan at any time (other
than the entry into such a plan in such a manner as to cause the sale of any securities subject to this Lock-Up Agreement during the Lock-Up Period). 

The Lock-Up Participant understands that this Lock-Up
Agreement is irrevocable and shall be binding upon the Lock-Up Participant’s heirs, legal representatives, successors and assigns. 

The Lock-Up Participant understands that if the Exchange Agreement (other than the provisions thereof
which survive termination) shall terminate or be terminated prior to Closing, then this Lock-Up Agreement shall be void and of no further force or effect. 

(Signature Page Follows) 

  
 8 

 
	
	Very truly yours,

  

	
	
	                
	(Name - Please Print)
	
	                
	(Signature)
	
	                
	(Name of Signatory, in the case of entities - Please Print)
	
	                
	(Title of Signatory, in the case of entities - Please Print)

  

			
	Address:Exhibit 10.13 

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT
AGREEMENT (this “Agreement”), effective as of the November 1, 2018 (the “Effective Date”), is
by and between CONVERSIONPOINT TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and CHRISTOPHER
JAHNKE (the “Executive”).

 

1.           Definitions.
In addition to the capitalized terms defined elsewhere herein, the following definitions shall be in effect under this Agreement:

 

(a)          “Affiliate”
means, with respect to any entity, any person or entity, directly or indirectly controlling or controlled by or under direct or
indirect common control with such entity.

 

(b)          “Board”
means the Board of Directors of the Company.

 

(c)          “Business”
means e-commerce technology platform.

 

(d)          “Cause”
means: (i) the Executive’s material breach of this Agreement and such breach is not cured by the Executive within thirty
(30) days after written notice from the Company; (ii) the Executive’s failure to perform Executive’s material duties
and obligations under this Agreement (other than during any period of Disability) and such failure is not cured by the Executive
within thirty (30) days after written notice from the Company; (iii) the Executive’s material malfeasance or material misconduct
in connection with the performance of Executive’s duties hereunder and such conduct is not cured by the Executive within
thirty (30) days after written notice from the Company; or (iv) the Executive’s conviction of, or pleading guilty or nolo
contendere to, a felony or the equivalent thereof, any other crime having as its predicate element fraud, dishonesty, misappropriation,
moral turpitude, or theft.

 

(e)          “Disability”
means and shall be deemed to have occurred if, in the Board’s reasonable discretion, after consultation with a physician
selected by the Board, the Executive shall have been unable to perform the essential functions of the Executive’s duties,
even with reasonable accommodation if required by law, for a period of not less than one hundred twenty (120) consecutive days,
or one hundred eighty (180) total days, during any twelve (12) month period. The Executive shall cooperate in submitting to medical
examinations and providing medical records to the physician selected by the Board as reasonably requested by the Board in making
a determination of Disability hereunder.

 

(f)          “Good
Reason” means any of the following actions if taken without the Executive’s prior written consent: (i) any material
failure by the Company to comply with its obligations under Paragraph 5 (Compensation and Related Matters), or Paragraph 13 (Assumption
by Successor); (ii) a reduction in the Executive’s responsibilities or duties except in accordance with the terms of this
Agreement; (iii) any relocation of the Executive’s principal place of business of 25 miles or more from the principal place
of business existing as of the date hereof; (iv) assignment by the Company of duties that are inconsistent with the Executive’s
role; (v) the reduction in title of the Executive; or (vi) requiring Executive to travel in excess
of twenty (20) days each quarter.

 

     

     

    

 

2.           Employment.
The Company agrees to employ the Executive, and the Executive agrees to be employed by the Company,
for the period set forth in Paragraph 3, in the position and with the duties and responsibilities set forth in Paragraph 4, and
upon the other terms and conditions set out in this Agreement.

 

3.           Term.
The term of the Agreement shall commence on the Effective Date and, shall end at 12:00 a.m. midnight
on the day immediately preceding the Three (3) Year anniversary thereof, unless earlier terminated as provided herein (the “Initial
Term”). The Initial Term shall be automatically extended for successive one (1) year terms after the expiration of the
Initial Term, unless either the Company or the Executive provides the other party written notice no more than ninety (90) days
and no less than thirty (30) days prior to the expiration of the Initial Term or any renewal term of such party’s desire
not to renew this Agreement (the Initial Term, as so extended, the “Employment Term”).

 

4.           Position
and Duties.

 

(a)          During
the Employment Term, the Executive shall serve as the Chief Marketing Officer of the Company. The Executive shall serve and perform
such other duties, functions, responsibilities, and authority as are from time to time delegated to the Executive by the Board
or the Company’s Chief Executive Officer; provided, however, that such duties, functions, responsibilities, and authority
are reasonable and customary for a person serving in the same or similar capacity of an enterprise comparable to the Company.

 

(b)          During
the Employment Term, the Executive shall devote sufficient business time, skill, attention and effort to all facets of the
business and affairs of the Company and will use Executive’s efforts to discharge fully, faithfully, and efficiently the
duties and responsibilities delegated and assigned to the Executive in or pursuant to this Agreement; provided, however, nothing
herein shall be construed as providing that Executive may not engage in outside business activities.

 

5.           Compensation
and Related Matters.

 

(a)          Base
Salary. The Company shall pay the Executive a base salary at the annual rate of not less than Three Hundred Thirty Five Thousand
Dollars (USD $335,000), provided, however, such base salary shall be earned monthly and payable “on a salary basis”
under applicable federal law (“Base Salary”). During the Employment Term, the Base Salary will be reviewed annually
and is subject to adjustment at the discretion of the Board, but in no event may the Company pay the Executive a Base Salary less
than that set forth above during the Employment Term. Payment of all compensation to the Executive hereunder shall be made in accordance
with the terms of this Agreement and applicable Company policies in effect from time to time, including normal payroll practices,
and shall be subject to all applicable withholdings and taxes.

 

(b)          Bonus.
Executive shall be entitled to receive a bonus based on revenue and EBITDA targets and other milestones to be agreed upon
between the Company and the Executive from time to time (the “Bonus”); provided, however, the target bonus shall
be a minimum of $200,000 per annum (the “Target Bonus”). Any Bonus shall be paid at such time as the Company
customarily pays bonuses; provided that such bonus shall be paid no later than thirty (30) days after the end of the monthly, quarterly
or annual period, as applicable, during which it was earned.

 

    	2

     

    

 

(c)          Employee
Benefits and Perquisites. During the Employment Term, the Executive will be entitled to (i) participate in all employee benefit
plans, programs, arrangements or policies that are from time to time made available by the Company generally to its senior executives,
including, without limitation, the Company’s life insurance, long-term disability, and health plans (“Employee Benefits”);
and (ii) the perquisites and other fringe benefits that are from time to time made available by the Company generally to its
senior executives and to such perquisites and fringe benefits that are from time to time made available by the Company to the Executive
in particular, subject to any applicable terms and conditions of any specific perquisite or other fringe benefit; provided, however,
that nothing contained herein shall be deemed to require the Company to adopt, maintain or provide any particular plan, program,
arrangement, policy, perquisite or fringe benefit. The Executive shall be required to comply with the conditions attendant to coverage
by such plans and shall comply with and be entitled to benefits only in accordance with the terms and conditions of such plans
as they may be amended from time to time. The Executive agrees to cooperate and participate in any medical or physical examinations
as may be required in connection with the applications for such life and/or disability insurance policies.

 

(d)          Expenses.
The Executive shall be entitled to receive reimbursement for all reasonable and necessary business expenses incurred by the Executive
in performing Executive’s duties and responsibilities under this Agreement, consistent with the Company’s policies
or practices as may from time to time be in effect for reimbursement of expenses incurred by other Company senior executives. All
expenses shall be reimbursed within fifteen (15) days after Executive submits an expense report and any required documentation.
Notwithstanding any Company policy or practice to the contrary, in order to be reimbursable hereunder, any such expenses shall
have been submitted to the Company with documentation no later than thirty (30) days after the Employment Termination Date.

 

(e)          Vacations.
The Executive shall be eligible for vacation, sick pay, and other paid and unpaid time off in accordance with the policies and
practices of the Company as may from time to time be in effect.

 

(f)          Indemnification.
The Company shall indemnify the Executive, to the maximum extent permitted by applicable law, against all costs, charges and expenses
incurred or sustained by Executive in connection with any action, suit or proceeding to which he may be made a party by reason
of being an officer, director, employee, contractor or agent of the Company or of any subsidiary or affiliate of the Company or
any other corporation for which Executive serves as an officer, director, or employee at the Company’s request.

 

6.           Termination
of Employment.

 

(a)          Death.
This Agreement shall terminate automatically upon the Executive’s death.

 

    	3

     

    

 

(b)          Disability.
The Company may terminate this Agreement at any time upon the Board’s determination of the Executive’s Disability;
provided, however, that such termination must occur while the Disability is in existence and before the Executive returns to work
at the Company on a full time basis.

 

(c)          Termination
by the Company for Cause. The Company may immediately terminate this Agreement after the Board’s determination that this
Agreement may be terminated for Cause.

 

(d)          Termination
by the Executive (Resignation). The Executive may terminate this Agreement for any reason, upon at least ten (10) days advance
prior written notice to the Company.

 

(e)          Termination
by the Company Without Cause. The Company may terminate this Agreement without Cause upon sixty (60) days’ advance prior
written notice to Executive; provided, however, notwithstanding the foregoing, the Company may elect to terminate this Agreement
immediately and provide the Executive with Executive’s Base Salary and other employment benefits during the notice period.

 

(f)          Termination
by the Executive for Good Reason. The Executive may terminate this Agreement for Good Reason. To exercise Executive’s
right to terminate for Good Reason, the Executive must provide written notice to the Company of Executive’s belief that Good
Reason exists, and such notice shall describe the circumstance believed to constitute Good Reason. The Company shall have thirty
(30) days to remedy any circumstances constituting Good Reason. If not remedied within that 30-day period, the Executive may submit
a Notice of Termination.

 

(g)          Notice
of Termination. Any termination of the Executive’s employment by the Company or the Executive (other than a termination
pursuant to Paragraph 6(a)) shall be communicated by a Notice of Termination. A “Notice of Termination” is a
written notice delivered in the manner set forth in Paragraph 11 hereof that must (i) indicate the specific termination provision
in this Agreement relied upon, and (ii) specify the Employment Termination Date.

 

(h)          Employment
Termination Date. The Employment Termination Date shall be as follows: (i) if the Executive’s employment is terminated
by Executive’s death, the date of Executive’s death; (ii) if the Executive’s employment is terminated pursuant
to any other provision of this Agreement, the date specified in the Notice of Termination (the “Employment Termination
Date”).

 

(i)          Transition
Period. Upon termination or expiration of this Agreement, and for a period of thirty (30) days thereafter (the “Transition
Period”), the Executive agrees to make Executive available to assist the Company with transition projects assigned to
Executive by the Board. The Executive will be paid at an agreed upon hourly rate for any work performed by the Executive for the
Company during the Transition Period.

 

    	4

     

    

 

7.           Compensation
Upon Termination of Employment.

 

(a)          Death.
Upon termination of this Agreement because of the Executive’s death, (i) the Company shall pay the Executive’s estate
the accrued and unpaid portion of the Executive’s Base Salary and all bonuses earned for services provided through the Employment
Termination Date (the “Compensation Payment”); (ii) the Company shall pay the Executive’s estate any reimbursement
for business travel and other expenses to which the Executive is entitled hereunder (the “Reimbursement”), and
(iii) any unvested portion of any options, stock or other securities of Company or any of its Affiliates granted to Executive which
are subject to vesting (“Unvested Securities”), shall immediately be issued (in the case of the stock grants)
and become exercisable (in the case of the stock options, warrants or other convertible securities), regardless of the vesting
or termination provisions of such Unvested Securities. For purposes of clarity, to the extent the vesting or other provisions of
any Unvested Securities conflict with the terms of this Section, the terms of this Section shall govern.

 

(b)          Disability.
Upon termination of this Agreement by the Company due to Disability pursuant to Paragraph 6(b), (i) the Company shall pay the Executive
the Compensation Payment; (ii) the Company shall pay the Executive the Reimbursement; and (iii) any Unvested Securities shall immediately
be issued (in the case of the stock grants) and become exercisable (in the case of the stock options, warrants or other convertible
securities). For purposes of clarity, to the extent the vesting or other provisions of any Unvested Securities conflict with the
terms of this Section, the terms of this Section shall govern.

 

(c)          Termination
for Cause. Upon termination of this Agreement by the Company for Cause pursuant to Paragraph 6(c), the Company shall pay the
Executive (i) the Compensation Payment; and (ii) the Reimbursement.

 

(d)          Termination
by the Executive (Resignation). Upon Termination of this Agreement by the Executive pursuant to Paragraph 6(d), the Company
shall pay the Executive (i) the Compensation Payment; and (ii) the Reimbursement.

 

(e)          Termination
by the Company Without Cause. Upon termination of this Agreement by the Company without Cause pursuant to Paragraph 6(e),
or by Executive for Good Reason pursuant to Paragraph 6(f), or upon a decision by the Company not to renew the Employment Term
pursuant to Paragraph 3: (i) the Company shall pay the Executive the Compensation Payment; (ii) the Company shall pay the Executive
the Reimbursement; (iii) any Unvested Securities shall immediately be issued (in the case of the stock grants) and become exercisable
or convertible (in the case of the stock options, warrants or other convertible securities); (iv) the Company shall pay the Executive,
as severance, a sum equal to 12 months Base Salary, as adjusted pursuant to Section 5(a) (the “Severance”);
(v) the Company shall continue to provide Employee with Employee Benefits for 12 months, or reimburse Employee for the expense
of obtaining equivalent benefits; and (vi) the Company shall pay the executive an amount equal to the greater of 100% of the Bonus
paid to the Executive during the prior 12 months, and 100% of the Target Bonus. The Severance shall be payable in one lump sum
payment as of the effective date of the termination, and shall be subject to all applicable withholdings and taxes.

 

    	5

     

    

 

(f)          No
Effect on Other Benefits. The payments provided for in Paragraphs 7(a) through 7(e) do not limit the entitlement of the Executive
or Executive’s estate or beneficiaries to any amounts payable pursuant to the terms of any applicable disability insurance
plan, policy, or similar arrangement that is maintained by the Company for the Executive’s benefit or to any death or other
vested benefits to which the Executive may be entitled under any life insurance, stock ownership, stock options, or other benefit
plan or policy that is maintained by the Company for the Executive’s benefit.

 

(g)          No
Mitigation. The Executive will not be required to mitigate the amount of any payment provided for in this Agreement by seeking
other employment or otherwise, nor will the amount of any payment provided for under this Agreement be reduced by any profits,
income, earnings, or other benefits received by the Executive from any source other than the Company or its successor.

 

(h)          Exercise
or Conversion of Vested Securities. Unless Executive is terminated for Cause, notwithstanding any provision to the contrary
in any stock option plan, stock option agreement, grant agreement, restricted stock unit agreement, or other agreement entered
into between the Company or any affiliate of the Company, on the one hand, and the Executive, on the other hand, or any benefit
plan, stock option plan, or other plan governing securities of the Company or any of the Company’s affiliates issued to the
Executive, whether or not such agreement is entered into, or plan is adopted, prior to or after the date hereof, all convertible
securities held by the Executive that are subject to exercise or conversion, shall remain exercisable or convertible until the
later of (a) the date such exercise or conversion rights expire under the terms of the applicable grant agreement or plan, and
(b) two (2) years after termination of this Agreement.

 

8.           Survival.
The expiration or termination of this Agreement will not impair the rights or obligations of any party hereto that accrue hereunder
prior to such expiration or termination, including, but not limited to, the Company’s obligations under Paragraphs 5(f) and
7.

 

9.           Withholding
Taxes. The Company shall withhold from any payments to be made to the Executive pursuant to this Agreement such amounts (including
social security contributions and federal income taxes) as shall be required by federal, state, and local withholding tax laws.

 

10.          Notices.
All notices, requests, demands, and other communications required or permitted to be given or made by either party shall be in
writing and shall be deemed to have been duly given or made (a) when delivered personally, or (b) when deposited and sent via overnight
courier, to the party for which intended at the following addresses (or at such other addresses as shall be specified by the parties
by like notice, except that notices of change of address shall be effective only upon receipt):

 

If to the Company, at:

 

Conversionpoint Technologies

840 Newport Center Drive, Suite 450

Newport Beach CA 92660

 

If to the Executive, at the Executive’s then-current home
address on file with the Company.

 

    	6

     

    

 

Notice
so given shall, in the case of overnight courier, be deemed to be given and received on the date of actual delivery and, in the
case of personal delivery, on the date of delivery.

 

11.          Binding
Effect: No Assignment by the Executive: No Third-Party Benefit. This Agreement shall be binding upon and inure to the benefit
of the parties and their respective heirs, legal representatives, successors, and assigns. The Executive shall not have any right
to pledge, hypothecate, anticipate, or in any way create a lien upon any payments or other benefits provided under this Agreement;
and no benefits payable under this Agreement shall be assignable in anticipation of payment either by voluntary or involuntary
acts, or by operation of law, except by will or pursuant to the laws of descent and distribution. Nothing in this Agreement, express
or implied, is intended to or shall confer upon any person other than the parties, and their respective heirs, legal representatives,
successors, and permitted assigns, any rights, benefits, or remedies of any nature whatsoever under or by reason of this Agreement.

 

12.          Assumption
by Successor. The Company shall require any successor or assignee (whether direct or indirect, by purchase, merger, consolidation,
or otherwise) to all or substantially all of the business and/or assets of the Company, by agreement in writing in form and substance
reasonably satisfactory to the Executive, expressly, absolutely, and unconditionally to assume and agree to perform this Agreement
in the same manner and to the same extent that the Company would be required to perform it if no such succession or assignment
had taken place. As used in this Agreement, “Company” shall include any successor or assignee (whether direct or indirect,
by purchase, merger, consolidation, or otherwise) to all or substantially all the business and/or assets of the Company that executes
and delivers the agreement provided for in this Paragraph or that otherwise becomes obligated under this Agreement by operation
of law.

 

13.          Arbitration.
The parties agree that any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be resolved
exclusively by confidential, final and binding arbitration administered by the American Arbitration Association (“AAA”)
under its Commercial Arbitration Rules. The arbitration will take place in Orange County, California, or another location mutually
acceptable to the parties. All disputes shall be resolved by one (1) arbitrator. The arbitrator will have the authority to award
the same remedies, damages, and costs that a court could award, and will have the additional authority to award specific performance
and/or injunctive or other relief in order to enforce or prevent any violations of the provisions hereof (without requiring the
posting of a bond or other security). The arbitrator shall issue a reasoned award explaining the decision, the reasons for the
decision, and any damages or other relief awarded. The arbitrator’s decision will be final and binding. The judgment on the
award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This provision
and any decision and award hereunder can be enforced under the Federal Arbitration Act.

 

14.          Governing
Law and Venue. This Agreement shall be governed by, construed and enforced in accordance with the laws of the State of California,
without regard to conflict of laws rules or principles which might refer the governance or construction of this Agreement to the
laws of another jurisdiction. Any action or arbitration in regard to this Agreement or arising out of its terms and conditions
shall be instituted and litigated only in Orange County, California.

 

    	7

     

    

 

15.          Entire
Agreement. This Agreement contains the entire agreement among the parties concerning the subject matter hereof and supersedes
all prior agreements and understandings, written and oral, between the parties with respect to the subject matter of this Agreement,
except that all confidentiality, assignment, and non-disclosure provisions and agreements between the Executive and the Company
are still in force and non superseded.

 

16.          Modification:
Waiver. No amendment, modification or waiver of this Agreement shall be effective unless it is in writing and signed by the
Executive and by a duly authorized representative of the Company (other than the Executive). Each party acknowledges and agrees
that no breach of this Agreement by the other party or failure to enforce or insist on its or Executive’s rights under this
Agreement shall constitute a waiver or abandonment of any such rights or defenses to enforcement of such rights.

 

17.          Severability.
If any provision of this Agreement shall be determined by a court or arbitrator to be invalid or unenforceable, the remaining provisions
of this Agreement shall not be affected thereby, shall remain in full force and effect, and shall be enforceable to the fullest
extent permitted by applicable law.

 

18.          Counterparts.
This Agreement may be executed by the parties in any number of counterparts, each of which shall be deemed an original, but all
of which shall constitute one and the same agreement. Counterparts delivered by electronic mail or facsimile shall be effective.

 

IN WITNESS WHEREOF, the Company and the Executive have
executed this Agreement on the date first written above.

 

	 	COMPANY:
	 	 
	 	
        CONVERSIONPOINT

        TECHNOLOGIES, INC. a Delaware corporation

	 	 
	Dated: November 1, 2018	By: 	/s/ Robert Tallack
	 	 	Robert Tallack, CEO

 

	 	EXECUTIVE:
	 	 
	Dated: November 1, 2018	/s/ Christopher Jahnke
	 	Christopher Jahnke
	 	 
	 	ADDRESS:	 
	 	 	 

 

    	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]